4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $204,388.32 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 5,833 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $35.04, for a total value of $204,388.32. Following the transaction, the insider now owns 1,737 shares of the company’s stock, valued at $60,864.48. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Scott Bizily also recently made the following trade(s):

• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.27, for a total transaction of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.67, for a total value of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.50, for a total transaction of $171,710.00.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock opened at $31.86 on Monday. The stock has a market cap of $1.59 billion, a PE ratio of -11.98 and a beta of 2.86. The stock’s fifty day moving average is $27.35 and its two-hundred day moving average is $18.91. 4D Molecular Therapeutics, Inc. has a 1-year low of $9.44 and a 1-year high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The business had revenue of ($0.02) million for the quarter, compared to analyst estimates of $4.67 million. 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. On average, research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on FDMT. BMO Capital Markets increased their target price on shares of 4D Molecular Therapeutics from $50.00 to $70.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 1st. Royal Bank of Canada boosted their target price on 4D Molecular Therapeutics from $25.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $81.00 price target on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.44.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of FDMT. Swiss National Bank grew its stake in shares of 4D Molecular Therapeutics by 6.9% in the 1st quarter. Swiss National Bank now owns 57,000 shares of the company’s stock valued at $862,000 after purchasing an additional 3,700 shares during the last quarter. JPMorgan Chase & Co. grew its position in 4D Molecular Therapeutics by 29.7% in the 1st quarter. JPMorgan Chase & Co. now owns 367,545 shares of the company’s stock valued at $5,557,000 after buying an additional 84,158 shares during the last quarter. Bank of New York Mellon Corp increased its stake in 4D Molecular Therapeutics by 1.1% in the 1st quarter. Bank of New York Mellon Corp now owns 101,322 shares of the company’s stock valued at $1,532,000 after buying an additional 1,136 shares during the period. MetLife Investment Management LLC raised its position in 4D Molecular Therapeutics by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 17,379 shares of the company’s stock worth $263,000 after buying an additional 6,197 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of 4D Molecular Therapeutics by 14.3% in the 1st quarter. Rhumbline Advisers now owns 35,097 shares of the company’s stock worth $531,000 after acquiring an additional 4,382 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.